Australia, Aug. 26 -- Terns Pharmaceuticals Inc., owns the trademark (2528171) for 'TERNS' till March 6, 2035.

Status: registered: Registered/protected

Classes: 5 [Pharmaceutical preparations, namely, small-molecule drugs; Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; Peptides for pharmaceutical purposes], 42 [Pharmaceutical and biologic development services, namely, development of small-molecule drugs for use in humans; Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; Research and development services in the field of pharmaceutical and biologic preparations; Research and development services in the field of oncology-related diseases and disorders; Research and development services in the field of metabolic-related diseases and disorders; Research and development services in the field of endocrine-related diseases and disorders; Research and development services in the fields of diabetes and obesity-related diseases and disorders; Research and development services in the field of peptide pharmaceutical preparations; Providing medical and scientific research information in the field of small-molecule drugs; Providing medical and scientific research information in the field of clinical trials and post-market trials; Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders], 5 [Pharmaceutical preparations, namely, small-molecule drugs;Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders;Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders;Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders;Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders;Peptides for pharmaceutical purposes] and 42 [Pharmaceutical and biologic development services, namely, development of small-molecule drugs for use in humans;Research and development services in the fields of diabetes and obesity-related diseases and disorders;Research and development services in the field of peptide pharmaceutical preparations;Providing medical and scientific research information in the field of small-molecule drugs;Providing medical and scientific research information in the field of clinical trials and post-market trials;Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders;Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders;Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders;Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders;Pharmaceutical and biologic development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders;Research and development services in the field of pharmaceutical and biologic preparations;Research and development services in the field of oncology-related diseases and disorders;Research and development services in the field of metabolic-related diseases and disorders;Research and development services in the field of endocrine-related diseases and disorders]

Type of Mark: Word

Date of Acceptance: June 16

Registration Advertised: Aug. 25

For further details contact PHILLIPS ORMONDE FITZPATRICK.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2528171.

Disclaimer: Curated by HT Syndication.